Age Labs has developed EPIPHANY, a machine learning-based biomarker discovery platform. Using EPIPHANY, we are developing biomarkers for the early detection of diseases and to predict drug response. We focus on aging and immunology. Our first diagnostic candidate is a test for the early detection of rheumatoid arthritis. We are also developing biomarkers for COVID-19 severity and for measuring biological age and frailty.
Rheumatoid arthritis affects about 1% of the world’s population and can cause permanent joint damage and disability. Clinicians today need better diagnostic tests that catch the disease earlier and help guide treatment.
The project is a collaboration with Diakonhjemmet Hospital, Fürst Medical Laboratory, the Norwegian Institute of Public Health, and Oslo University Hospital Rikshospitalet.
Aging is the most important risk factor for the most common chronic diseases, such as heart disease, cancer and dementia. In order to prevent age-related diseases we need to measure the aging process itself.
The project is a collaboration with Fürst Medical Laboratory, the Norwegian Institute of Public Health, and Oslo University Hospital Rikshospitalet.
COVID-19 is an unpredictable disease with a high hospitalization rate and a high mortality rate. We aim to develop a blood test that can be used by clinicians to predict risk of severe disease in COVID-19 and to guide therapy for their patients.
The project is a collaboration between the Norwegian Institute of Public Health, Bærum Hospital Vestre Viken and Oslo University Hospital.